EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data?

被引：6

作者：

Antonanzas, F. ^{[1
]}

Juarez-Castello, C. A. ^{[1
]}

Rodriguez-Ibeas, R. ^{[1
]}

机构：

[1] Univ La Rioja, Dept Econ, Logrono 26004, Spain

来源：

EUROPEAN JOURNAL OF HEALTH ECONOMICS | 2018年 / 19卷 / 07期

关键词：

D O I：

10.1007/s10198-017-0944-0

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

收藏

页码：905 / 907

页数：3

相关论文

共 6 条

[1] Should the patent system for pharmaceuticals be replaced? A theoretical approach
Antonanzas, Fernando
Rodriguez-Ibeas, Roberto
Juarez-Castello, Carmelo A.
[J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (05) : 617 - 626
[2] Pharmaceutical patents, R&D incentives and access to new drugs: new ways of progress at the crossroad
Antonanzas, Fernando
Juarez-Castello, Carmelo
Rodriguez-Ibeas, Roberto
[J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2011, 12 (05) : 393 - 395
[3] European Medicines Agency, 2017, COND MARK AUTH REP Y
[4] European Medicines Agency, 2017, PRIME PRIOR MED
[5] Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals
Kim, Chul
Prasad, Vinay
[J]. JAMA INTERNAL MEDICINE, 2015, 175 (12) : 1992 - 1994
[6] UK Government, 2016, ACC ACC REV FIN REP